Find Pitavastatin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

FINISHED DOSAGE FORMULATIONS

0

Canada

0

Australia

0

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

92RELATED EXCIPIENT COMPANIES

145EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

Annual Reports

NA

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Pitavastatin calcium, 147526-32-7, Livalo, Nisvastatin, Nk-104, Itavastatin calcium
Molecular Formula
C50H46CaF2N2O8
Molecular Weight
881.0  g/mol
InChI Key
RHGYHLPFVJEAOC-FFNUKLMVSA-L
FDA UNII
IYD54XEG3W

Pitavastatin
Pitavastatin Calcium is a calcium salt formulation of pitavastatin, a novel statin that induces plaque regression and elevates HDL-cholesterol levels.
1 2D Structure

Pitavastatin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
calcium;(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
2.1.2 InChI
InChI=1S/2C25H24FNO4.Ca/c2*26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31;/h2*1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31);/q;;+2/p-2/b2*12-11+;/t2*18-,19-;/m11./s1
2.1.3 InChI Key
RHGYHLPFVJEAOC-FFNUKLMVSA-L
2.1.4 Canonical SMILES
C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)[O-])O)O)C4=CC=C(C=C4)F.C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)[O-])O)O)C4=CC=C(C=C4)F.[Ca+2]
2.1.5 Isomeric SMILES
C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2]
2.2 Other Identifiers
2.2.1 UNII
IYD54XEG3W
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (e,3r,5s)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic Acid

2. Itavastatin

3. Itavastatin Calcium

4. Nisvastatin

5. Nk 104

6. Nk-104

7. P 872441

8. P-872441

9. Pitavastatin

10. Pitavastatin Calcium

11. Pitavastatin Lactone

2.3.2 Depositor-Supplied Synonyms

1. Pitavastatin Calcium

2. 147526-32-7

3. Livalo

4. Nisvastatin

5. Nk-104

6. Itavastatin Calcium

7. Pitavastatin Calcium Salt

8. Calcium (3r,5s,e)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate

9. Nk 104

10. Iyd54xeg3w

11. Chebi:71258

12. Calcium;(e,3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate

13. P-872441

14. Pitavastatin Calcium (jan)

15. Pitavastatin Calcium [jan]

16. Alipza

17. Flovas

18. Livazo

19. Unii-iyd54xeg3w

20. Nk 104 (acid)

21. Redevant

22. Ccris 8652

23. Livalo (tn)

24. Schembl22720

25. Bis((3r,5s,6e)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), Monocalcium Salt

26. Chembl1237061

27. Dtxsid4046448

28. Chebi:94569

29. Pitavastatin Hemicalcium;nk-104

30. Nks-104

31. Act02718

32. Mfcd01937979

33. Pitavastatin Calcium [mart.]

34. Pitavastatin Calcium [who-dd]

35. Akos015900407

36. Pitavastatin Calcium Salt [mi]

37. Am84441

38. Ks-1220

39. (+)-monocalciumbis{(3r,5s,6e)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-hepten

40. 111ge002

41. 6-heptenoic Acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, Calcium Salt (2:1), (s-(r*,s*-(e)))-

42. Pitavastatin Calcium [orange Book]

43. D01862

44. Q-201590

45. Q27139472

46. (+)-monocalciumbis[(3r,5s,6e)-7-[2-cyclopropyl-4(4-fluorophenyl)-3-quinolyl]3,5-dihydroxy-6-hepteno Ate]

47. (3r,5s,6e)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic Acid Hemicalcium Salt

48. Bis((3r,5s,6e)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate) Monocalcium Salt

49. Calcium (3r,5s,e)-7-(2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-3,5-dihydroxyhept-6-enoate

50. Calcium Bis{(3r,5s,6e)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate}

2.4 Create Date
2005-10-11
3 Chemical and Physical Properties
Molecular Weight 881.0 g/mol
Molecular Formula C50H46CaF2N2O8
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count12
Rotatable Bond Count14
Exact Mass880.2848136 g/mol
Monoisotopic Mass880.2848136 g/mol
Topological Polar Surface Area187 Ų
Heavy Atom Count63
Formal Charge0
Complexity626
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count2
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameLivalo
PubMed HealthPitavastatin (By mouth)
Drug ClassesAntihyperlipidemic
Active IngredientPitavastatin calcium
Dosage FormTablet
RouteOral
Strengtheq 4mg base; eq 2mg base; eq 1mg base
Market StatusPrescription
CompanyKowa

2 of 2  
Drug NameLivalo
PubMed HealthPitavastatin (By mouth)
Drug ClassesAntihyperlipidemic
Active IngredientPitavastatin calcium
Dosage FormTablet
RouteOral
Strengtheq 4mg base; eq 2mg base; eq 1mg base
Market StatusPrescription
CompanyKowa

5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. (See all compounds classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]; HMG-CoA Reductase Inhibitor [EPC]

USDMF

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed

01

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2013-09-14

Pay. Date : 2013-05-07

DMF Number : 27106

Submission : 2013-05-07

Status : Active

Type : II

blank

02

Hetero Drugs Ltd

India

USDMF

arrow
PEGS Boston Summit
Not Confirmed

02

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2013-09-22

Pay. Date : 2013-07-10

DMF Number : 27255

Submission : 2013-07-16

Status : Active

Type : II

blank

03

Kowa Co Ltd

India

USDMF

arrow
PEGS Boston Summit
Not Confirmed

03

Kowa Co Ltd

India
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 15303

Submission : 2001-02-16

Status : Inactive

Type : II

blank

04

Lupin Ltd

India

USDMF

arrow

05

PEGS Boston Summit
Not Confirmed

05

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2013-12-17

Pay. Date : 2013-03-28

DMF Number : 23488

Submission : 2010-01-27

Status : Active

Type : II

blank

06

Nissan Chemical Corp

Japan

USDMF

arrow
PEGS Boston Summit
Not Confirmed

06

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 14660

Submission : 2000-01-11

Status : Active

Type : II

blank

07

PEGS Boston Summit
Not Confirmed

07

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2013-09-22

Pay. Date : 2013-07-30

DMF Number : 25956

Submission : 2012-04-11

Status : Active

Type : II

blank

08

PEGS Boston Summit
Not Confirmed

08

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2013-09-19

Pay. Date : 2013-06-18

DMF Number : 27144

Submission : 2013-06-25

Status : Active

Type : II

blank

09

PEGS Boston Summit
Not Confirmed

09

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 26406

Submission : 2012-12-16

Status : Inactive

Type : II

blank

10

PEGS Boston Summit
Not Confirmed

10

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2013-09-22

Pay. Date : 2013-07-29

DMF Number : 27333

Submission : 2013-07-31

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Japanese Pharmacopoeia Pitavastatin Calcium Hydrate

Registration Number : 303MF10052

Registrant's Address : 5850-1 Higashine-ko, Higashine City, Yamagata Prefecture

Initial Date of Registration : 2021-03-26

Latest Date of Registration : 2026-05-07

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin calcium hydrate

Registration Number : 229MF10194

Registrant's Address : 2-36-1 Kanda Jimbocho, Chiyoda-ku, Tokyo

Initial Date of Registration : 2017-11-07

Latest Date of Registration : 2017-11-07

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin calcium hydrate

Registration Number : 229MF10090

Registrant's Address : 1978-96 Ogushi, Ube City, Yamaguchi Prefecture

Initial Date of Registration : 2017-05-01

Latest Date of Registration : 2020-04-02

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin calcium

Registration Number : 303MF10039

Registrant's Address : 1978-96 Ogushi, Ube City, Yamaguchi Prefecture

Initial Date of Registration : 2021-02-24

Latest Date of Registration : 2021-02-24

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin calcium (C)

Registration Number : 302MF10150

Registrant's Address : 110, MAGOKDONG-RO, GANGSEO-GU, SEOUL, KOREA

Initial Date of Registration : 2020-12-15

Latest Date of Registration : 2020-12-15

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin calcium hydrate "KBP"

Registration Number : 304MF10079

Registrant's Address : 174, Sirok-ro, Asan-si, Chungcheongnam-do, KOREA

Initial Date of Registration : 2022-05-25

Latest Date of Registration : 2022-05-25

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium C

Registration Number : 223MF10122

Registrant's Address : 2-5-1 Nihonbashi, Chuo-ku, Tokyo

Initial Date of Registration : 2011-07-28

Latest Date of Registration : 2015-05-25

blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium CZ

Registration Number : 307MF10091

Registrant's Address : 2-5-1 Nihonbashi, Chuo-ku, Tokyo

Initial Date of Registration : 2025-07-30

Latest Date of Registration : 2025-07-30

blank

09

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin calcium hydrate M

Registration Number : 304MF10026

Registrant's Address : 2-36-1 Kanda Jimbocho, Chiyoda-ku, Tokyo

Initial Date of Registration : 2022-02-02

Latest Date of Registration : 2022-02-02

blank

10

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium "A"

Registration Number : 224MF10148

Registrant's Address : 2nd Floor, Admin Block 27, Vandalooor kelambakkam Road, Keelakottaiyur Village, Melak...

Initial Date of Registration : 2012-07-31

Latest Date of Registration : 2025-10-08

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

Enaltec Labs

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEnaltec Labs –Delivering complex APIs with precision, innovation, and global compliance.

Flag India
Digital Content Digital Content

Pitavastatin Calcium IH

Date of Issue : 2022-12-16

Valid Till : 2025-12-15

Written Confirmation Number : WC-0544

Address of the Firm : Plot No. 825,826,827, Industrial Area, Sector-Ill, Pithampur, Dhar-454774, Madhy...

Company Banner

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium IH

Date of Issue : 2025-07-11

Valid Till : 2028-06-25

Written Confirmation Number : WC-0023

Address of the Firm : Sy. No\'s. 52,53,58,59,61 to 78, 127 & 128, Pydibhimavaram Village & Sy. No\'s. ...

blank

03

Hetero Drugs

India
PEGS Boston Summit
Not Confirmed
arrow

Hetero Drugs

India
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium IH

Date of Issue : 2022-09-30

Valid Till : 2025-08-08

Written Confirmation Number : WC-0066

Address of the Firm : Plot No 1, Hetero Infrastructure SEZ Ltd., N. Narasapuram, Anakapalli -531081, A...

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin IH

Date of Issue : 2025-07-07

Valid Till : 2028-07-14

Written Confirmation Number : WC-0021

Address of the Firm : Sy. Nos, 317,320,321,322,323,604 & 605, Pincode-502329, Rudraram (Village), Pata...

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium IHS

Date of Issue : 2025-08-08

Valid Till : 2028-07-25

Written Confirmation Number : WC-0027

Address of the Firm : Unit-ll, Sy. No. 14, Gaddapotharam Village, IDA, Khazipally, Jinnaram Mandal, Sa...

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium IH

Date of Issue : 2025-09-29

Valid Till : 2028-08-04

Written Confirmation Number : WC-0127

Address of the Firm : A1/B, SIPCOT Industrial Complex,\r\nKudikadu, Cuddalore -607005, Tamil Nadu, Ind...

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium IH

Date of Issue : 2025-08-29

Valid Till : 2028-08-28

Written Confirmation Number : WC-0084

Address of the Firm : Plot no. 26 to 29 & 31, Umraya Road, Vill-Dabhasa, Tal-Padra, Dist.: Vadodara, P...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

pitavastatin calcium

Registrant Name : Coapharm Bio Co., Ltd.

Registration Date : 2025-09-26

Registration Number : Su152-4-ND

Manufacturer Name : China Resources Double-Crane...

Manufacturer Address : No.3, Huatuo Road, West Zone, Lingang Economic and Technological Development Zone, Ca...

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

pitavastatin calcium

Registrant Name : Kolon Life Science Co., Ltd.

Registration Date : 2025-09-29

Registration Number : 1607-3-ND

Manufacturer Name : Kolon Life Science Co., Ltd.

Manufacturer Address : 54, Gibeopdosi 1-ro, Daesowon-myeon, Chungju-si, Chungcheongbuk-do

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin calcium hydrate

Registrant Name : Kyungbo Pharmaceutical Co., Ltd.

Registration Date : 2021-12-01

Registration Number : 1673-49-ND

Manufacturer Name : Kyungbo Pharmaceutical Co., ...

Manufacturer Address : 174 Silok-ro, Asan-si, Chungcheongnam-do  

blank

04

Samjin pharm Co. Ltd

South Korea
PEGS Boston Summit
Not Confirmed
arrow

Samjin pharm Co. Ltd

South Korea
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin calcium hydrate

Registrant Name : Samjin Pharmaceutical Co., Ltd.

Registration Date : 2026-01-16

Registration Number : 1324-4-ND

Manufacturer Name : Samjin Pharmaceutical Co., L...

Manufacturer Address : 156, Osongsaengmyeong 6-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin calcium hydrate

Registrant Name : Pharmapia Co., Ltd.

Registration Date : 2026-03-09

Registration Number : Su258-56-ND

Manufacturer Name : Shandong Qidu Pharmaceutical...

Manufacturer Address : No.17, Hongda Road, Linzi District, Zibo City, Shandong province, China.

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

pitavastatin calcium

Registrant Name : Eltech Pharmachem Co., Ltd.

Registration Date : 2026-01-23

Registration Number : Su2816-6-ND(B)

Manufacturer Name : Solara Active Pharma Science...

Manufacturer Address : A1/B, Sipcot Industrial Complex, Kudikadu Cuddalore-607 005.

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

pitavastatin calcium

Registrant Name : Hanyoung Pharm Co., Ltd.

Registration Date : 2022-07-18

Registration Number : Number 2816-6-ND(3)

Manufacturer Name : Solara Active Pharma Science...

Manufacturer Address : A-1/B, Sipcot Industrial Complex Kudikadu Village, Cuddalore - 607 005 Tamilnadu, Ind...

blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

pitavastatin calcium

Registrant Name : Sampung Pharmachem Co., Ltd.

Registration Date : 2025-01-14

Registration Number : Su582-19-ND

Manufacturer Name : Zenji Pharmaceuticals (Suzho...

Manufacturer Address : No.122, Xuqing Road, Xuguan Town, Suzhou, Jiangsu, China

blank

09

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

pitavastatin calcium

Registrant Name : Pharmapia Co., Ltd.

Registration Date : 2025-05-16

Registration Number : Su582-19-ND(1)

Manufacturer Name : Zenji Pharmaceuticals (Suzho...

Manufacturer Address : No.122, Xuqing Road, Xuguan Town, Suzhou, Jiangsu, China

blank

10

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

pitavastatin calcium

Registrant Name : Otran Korea Co., Ltd.

Registration Date : 2023-01-11

Registration Number : Su695-15-ND

Manufacturer Name : Shaoxing Jingxin Pharmaceuti...

Manufacturer Address : No. 31 Weisan Road, Hangzhou Bay, Shangyu Economic and Technological Development Area...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

PITAVASTATIN CALCIUM

NDC Package Code : 84386-139

Start Marketing Date : 2025-11-21

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (50kg/50kg)

Marketing Category : BULK INGREDIENT

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

PITAVASTATIN CALCIUM

NDC Package Code : 65862-811

Start Marketing Date : 2024-01-05

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (50kg/50kg)

Marketing Category : BULK INGREDIENT

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

PITAVASTATIN CALCIUM

NDC Package Code : 65977-0101

Start Marketing Date : 2009-08-03

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

PITAVASTATIN CALCIUM

NDC Package Code : 84206-0076

Start Marketing Date : 2024-08-08

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

PITAVASTATIN CALCIUM

NDC Package Code : 14501-0061

Start Marketing Date : 2010-03-29

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

PITAVASTATIN CALCIUM

NDC Package Code : 44343-001

Start Marketing Date : 2009-11-16

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Pitavastatin

About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...

LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product CDMO, offering formulation, analytical method development and testing, regulatory support, and commercial manufacturing. Supported by a network of over 220 accredited cGMP manufacturing partners and more than 100,000 sq. ft. of FDA-inspected cGMP manufacturing and warehouse space, LGM delivers secure, end-to-end solutions across multiple dosage forms. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
LGM Pharma CB

02

Enaltec Labs

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEnaltec Labs –Delivering complex APIs with precision, innovation, and global compliance.

Flag India
Digital Content Digital Content

Pitavastatin

About the Company : Enaltec, founded in 2006, specializes in developing and manufacturing complex, small-volume, technology-driven APIs at competitive prices, leveraging the India advantage for global...

Enaltec, founded in 2006, specializes in developing and manufacturing complex, small-volume, technology-driven APIs at competitive prices, leveraging the India advantage for global generic formulators. The company operates USFDA-approved and WHO-GMP-approved facilities, a DSIR-approved R&D center, GLP-compliant labs, and cGMP-certified plants. Enaltec has developed over 90 products for regulated and semi-regulated markets in just 16 years, driving advanced synthesis and analytical research. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin

About the Company : Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilities that adhere to G...

Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilities that adhere to GMP standards. We take great pride in producing top-notch intermediates through our fully backward-integrated process. Aptra Synthesis Private Limited (ASPL) stands as one of the rapidly emerging manufacturers of Active Pharmaceutical Ingredients (APIs), Pellets (Semi-finished Formulations), and Intermediates.
blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium

About the Company : Aspire group was established in the year 2000 with a motto of quality drug for better health of all. In its journey till date, aspire has developed enormous reputation, consistent ...

Aspire group was established in the year 2000 with a motto of quality drug for better health of all. In its journey till date, aspire has developed enormous reputation, consistent growth, unique technologies and world class quality healthcare products. Aspire is pioneer in manufacturing and sourcing unique healthcare products. True to the statement, “Where the future started yesterday” with a foresight on the current trends in the healthcare market, Aspire has grown from strength combining its research strength, Human resources and well established quality systems. Aspire has crossed numerous milestones in a comparatively short period since its inception.
blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium

About the Company : Boryung Pharmaceutical, aiming at the best not the biggest, started from the pharmacy since 1957 and has put a strong presence in Korean market as one of TOP leading pharmaceutical...

Boryung Pharmaceutical, aiming at the best not the biggest, started from the pharmacy since 1957 and has put a strong presence in Korean market as one of TOP leading pharmaceutical companies. Boryung has invested continually on research and development and made continuous efforts to produce high-quality products. Lately by developing new drug of Fimasartan(new chemical entity by Boryung's technology) with its own R&D, Boryung is accelerating its R&D activity to become global health care company. Also, synthetic API's & oncology formulation are core competence and have been attractive to many customers in regulated & non-regulated markets.
blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin

About the Company : Changzhou Pharmaceutical Factory (CPF) is a subsidiary company of Shanghai Pharma Holdings Co., Ltd., It is headquartered in Changzhou, Jiangsu Province, China. The company was fou...

Changzhou Pharmaceutical Factory (CPF) is a subsidiary company of Shanghai Pharma Holdings Co., Ltd., It is headquartered in Changzhou, Jiangsu Province, China. The company was founded in 1949 by (Tan Ruiting) with a registered capital of 108 million yuan and the company was restructured as a Changzhou pharmaceutical Factory under the aegis of the Shanghai Pharma Group. The company mainly involves leading pharmaceutical manufacturers a wide range of key Intermediates, Active pharmaceutical ingredients, and Finished Formulations that meet with global standards.
blank

07

CHEMO

Spain
PEGS Boston Summit
Not Confirmed
arrow

CHEMO

Spain
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin

About the Company : More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, ...

More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, and starts business activities trading with pharmaceutical raw materials. In the 80's, the company expanded its operations into the Industrial Business, developing and manufacturing active pharmaceutical ingredients (APIs) in Italy (Industriale Chimica) and in Spain (Quimica Sintetica). In the 90's, CHEMO starts developing and manufacturing high quality and technology finished dosage forms (FDFs).
blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium

About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...

Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Excipients, Herbal extracts, Formulation of Chinese & Western Medicine. With abundant economic strength, the group has successfully developed to a pharmaceutical group enterprise wich intergrets operation of medicine & related products, processing & manufacturing, and importation & exportation together.
blank

09

Polaris AI Pharma

South Korea
PEGS Boston Summit
Not Confirmed
arrow

Polaris AI Pharma

South Korea
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium

About the Company : Polaris AI Pharma is a dynamic company specializing in innovative pharmaceutical solutions. Leveraging cutting-edge AI technology, it focuses on drug discovery, development, and op...

Polaris AI Pharma is a dynamic company specializing in innovative pharmaceutical solutions. Leveraging cutting-edge AI technology, it focuses on drug discovery, development, and optimization to address unmet medical needs. Committed to advancing healthcare, Polaris AI Pharma combines scientific expertise with digital innovation to deliver impactful treatments.
blank

10

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Pitavastatin Calcium

About the Company : Shandong Qidu Pharmaceutical is a comprehensive and research-based drug production enterprise which produces IV solutions, oral preparations, APIs and so on. The products mainly in...

Shandong Qidu Pharmaceutical is a comprehensive and research-based drug production enterprise which produces IV solutions, oral preparations, APIs and so on. The products mainly involve basic infusions, intravenous nutrition liquid, plasma substitutes, anti-infective agents, anti tumor drugs, cardio-cerebrovascular drugs, internal secretion regulators, pharmaceutical packaging materials, medical supplies and so on.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Alirocumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypercholesterolemia.


Lead Product(s): Alirocumab,Pravastatin,Simvastatin,Fluvastatin,Atorvastatin,Pitavastatin,Rosuvastatin Calcium

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

Sponsor: Regeneron Pharmaceuticals

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 08, 2014

Sanofi Company Banner

01

Sanofi

France
arrow

Lead Product(s) : Alirocumab, Pravastatin, Simvastatin, Fluvastatin, Atorvastatin

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Alirocumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypercholesterolemia.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

April 08, 2014

Sanofi Company Banner

Details:

ABBV-722 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.


Lead Product(s): ABBV-722,Midazolam,Metformin,Digoxin,Pitavastatin,Sitagliptin Phosphate

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 05, 2026

Abbvie Company Banner

02

AbbVie Inc

U.S.A
arrow

Details : ABBV-722 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 05, 2026

Abbvie Company Banner
  • Development Update

Details:

Pitavastatin is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of erectile dysfunction.


Lead Product(s): Pitavastatin,Rosuvastatin Calcium

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Nizhpharm

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 10, 2026

blank

03

Lomonosov Moscow State University Medical Research and Educational Center

Country
arrow
PEGS Boston Summit
Not Confirmed

Lomonosov Moscow State University Medical Research and Educational Center

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Pitavastatin is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of erectile dysfunction.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 10, 2026

blank

Details:

Pitavastatin is a small molecule drug, which is currently being evaluated in Phase IV clinical studies for the treatment of hypercholesterolemia.


Lead Product(s): Pitavastatin,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 02, 2026

blank

04

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Pitavastatin is a small molecule drug, which is currently being evaluated in Phase IV clinical studies for the treatment of hypercholesterolemia.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 02, 2026

blank

Details:

Pitavastatin, a miscellaneous product targeting HMG-CoA reductase, shows promise in treating disseminated superficial actinic porokeratosis (DSAP).


Lead Product(s): Pitavastatin,Inapplicable

Therapeutic Area: Dermatology Brand Name: QTORIN pitavastatin

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 05, 2025

blank

05

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Pitavastatin, a miscellaneous product targeting HMG-CoA reductase, shows promise in treating disseminated superficial actinic porokeratosis (DSAP).

Product Name : QTORIN pitavastatin

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 05, 2025

blank

Details:

RO7795081 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Overweight.


Lead Product(s): RO7795081,Rosuvastatin Calcium,Pitavastatin

Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Undisclosed

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 21, 2025

blank

06

F. Hoffmann-La Roche

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

F. Hoffmann-La Roche

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Details : RO7795081 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Overweight.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

May 21, 2025

blank

Details:

Digoxin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anemia, Sickle Cell.


Lead Product(s): Digoxin,Pitavastatin,Metformin

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 07, 2025

blank

07

Novo Nordisk

Denmark
arrow
PEGS Boston Summit
Not Confirmed

Novo Nordisk

Denmark
arrow
PEGS Boston Summit
Not Confirmed

Details : Digoxin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anemia, Sickle Cell.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 07, 2025

blank

Details:

Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Pitavastatin,Ceftobiprole

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Biomedical Advanced Research and Development Authority

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 05, 2025

blank

08

Basilea Pharmaceutica

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Basilea Pharmaceutica

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Pitavastatin,Ceftobiprole

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Biomedical Advanced Research and Development Authority

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 05, 2025

blank
  • Development Update

Details:

Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Atherosclerosis.


Lead Product(s): Pitavastatin,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Daewon Pharm. Co., Ltd | Samjin Pharmaceutical

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 10, 2025

blank

09

Korea University Anam Hospital

Country
arrow
PEGS Boston Summit
Not Confirmed

Korea University Anam Hospital

Country
arrow
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Pitavastatin,Ezetimibe

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : Daewon Pharm. Co., Ltd | Samjin Pharmaceutical

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Atherosclerosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 10, 2025

blank
  • Development Update

Details:

Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoporosis.


Lead Product(s): Pitavastatin,Inapplicable

Therapeutic Area: Musculoskeletal Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: JW Pharmaceutical

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 11, 2024

blank

10

Seoul National University Bundang Hospital

Country
arrow
PEGS Boston Summit
Not Confirmed

Seoul National University Bundang Hospital

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoporosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 11, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Controlled & Modified Release

read-more
read-more

Lubricants & Glidants

read-more
read-more

Granulation

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Direct Compression

read-more
read-more

Empty Capsules

read-more
read-more

Emulsifying Agents

read-more
read-more

Co-Processed Excipients

read-more
read-more

Vegetarian Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Taste Masking

read-more
read-more

Solubilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Coloring Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Parenteral

read-more
read-more

Topical

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 147526-32-7 / Pitavastatin API manufacturers, exporters & distributors?

Pitavastatin manufacturers, exporters & distributors 1

19

PharmaCompass offers a list of Pitavastatin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Pitavastatin manufacturer or Pitavastatin supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pitavastatin manufacturer or Pitavastatin supplier.

API | Excipient name

Pitavastatin

Synonyms

Pitavastatin calcium, 147526-32-7, Livalo, Nisvastatin, Nk-104, Itavastatin calcium

Cas Number

147526-32-7

Unique Ingredient Identifier (UNII)

IYD54XEG3W

About Pitavastatin

Pitavastatin Calcium is a calcium salt formulation of pitavastatin, a novel statin that induces plaque regression and elevates HDL-cholesterol levels.

Pitavastatin Calcium Manufacturers

A Pitavastatin Calcium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pitavastatin Calcium, including repackagers and relabelers. The FDA regulates Pitavastatin Calcium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pitavastatin Calcium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Pitavastatin Calcium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Pitavastatin Calcium Suppliers

A Pitavastatin Calcium supplier is an individual or a company that provides Pitavastatin Calcium active pharmaceutical ingredient (API) or Pitavastatin Calcium finished formulations upon request. The Pitavastatin Calcium suppliers may include Pitavastatin Calcium API manufacturers, exporters, distributors and traders.

click here to find a list of Pitavastatin Calcium suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Pitavastatin Calcium USDMF

A Pitavastatin Calcium DMF (Drug Master File) is a document detailing the whole manufacturing process of Pitavastatin Calcium active pharmaceutical ingredient (API) in detail. Different forms of Pitavastatin Calcium DMFs exist exist since differing nations have different regulations, such as Pitavastatin Calcium USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Pitavastatin Calcium DMF submitted to regulatory agencies in the US is known as a USDMF. Pitavastatin Calcium USDMF includes data on Pitavastatin Calcium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pitavastatin Calcium USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Pitavastatin Calcium suppliers with USDMF on PharmaCompass.

Pitavastatin Calcium JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Pitavastatin Calcium Drug Master File in Japan (Pitavastatin Calcium JDMF) empowers Pitavastatin Calcium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Pitavastatin Calcium JDMF during the approval evaluation for pharmaceutical products. At the time of Pitavastatin Calcium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Pitavastatin Calcium suppliers with JDMF on PharmaCompass.

Pitavastatin Calcium KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Pitavastatin Calcium Drug Master File in Korea (Pitavastatin Calcium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pitavastatin Calcium. The MFDS reviews the Pitavastatin Calcium KDMF as part of the drug registration process and uses the information provided in the Pitavastatin Calcium KDMF to evaluate the safety and efficacy of the drug.

After submitting a Pitavastatin Calcium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pitavastatin Calcium API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Pitavastatin Calcium suppliers with KDMF on PharmaCompass.

Pitavastatin Calcium WC

A Pitavastatin Calcium written confirmation (Pitavastatin Calcium WC) is an official document issued by a regulatory agency to a Pitavastatin Calcium manufacturer, verifying that the manufacturing facility of a Pitavastatin Calcium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pitavastatin Calcium APIs or Pitavastatin Calcium finished pharmaceutical products to another nation, regulatory agencies frequently require a Pitavastatin Calcium WC (written confirmation) as part of the regulatory process.

click here to find a list of Pitavastatin Calcium suppliers with Written Confirmation (WC) on PharmaCompass.

Pitavastatin Calcium NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pitavastatin Calcium as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Pitavastatin Calcium API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Pitavastatin Calcium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Pitavastatin Calcium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pitavastatin Calcium NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Pitavastatin Calcium suppliers with NDC on PharmaCompass.

Pitavastatin Calcium GMP

Pitavastatin Calcium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Pitavastatin Calcium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Pitavastatin Calcium GMP manufacturer or Pitavastatin Calcium GMP API supplier for your needs.

Pitavastatin Calcium CoA

A Pitavastatin Calcium CoA (Certificate of Analysis) is a formal document that attests to Pitavastatin Calcium's compliance with Pitavastatin Calcium specifications and serves as a tool for batch-level quality control.

Pitavastatin Calcium CoA mostly includes findings from lab analyses of a specific batch. For each Pitavastatin Calcium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Pitavastatin Calcium may be tested according to a variety of international standards, such as European Pharmacopoeia (Pitavastatin Calcium EP), Pitavastatin Calcium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pitavastatin Calcium USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty